106 results
Page 2 of 6
ARS
llgk7v0p472ylu2kedsk
1 May 23
Annual report to shareholders
1:52pm
424B5
67jxtwrgyviff0b47q4x
14 Sep 22
Prospectus supplement for primary offering
4:12pm
424B5
2magzqs tfwkyl11ox
13 Sep 22
Prospectus supplement for primary offering
5:19pm
8-K
EX-99.1
oqdv 2i46fr
12 Sep 22
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
7:54am
8-K
EX-99.2
qte7fto3d i8osus8
12 Sep 22
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
7:54am
424B3
trsnaq imom3
11 Jul 22
Prospectus supplement
4:32pm
POS AM
btk cz4s9
1 Jul 22
Prospectus update (post-effective amendment)
4:17pm
S-3
qm2ezpo9u3d7sgedb
1 Jul 22
Shelf registration
4:13pm
S-3
EX-1.2
ld4j7erqy sd3
1 Jul 22
Shelf registration
4:13pm
S-3
EX-4.7
kii6nno jh0s
1 Jul 22
Shelf registration
4:13pm
S-3
EX-4.6
541tr5zce
1 Jul 22
Shelf registration
4:13pm
424B3
dxg4g2xufm6qnj w5eu
13 May 22
Prospectus supplement
8:18am
DEF 14A
kih 9vpyljwsh34
28 Apr 22
Definitive proxy
8:36am